Marwan Fakih: We were the first to define the resistance of liver metastatic disease to IO in MSS CRC and to make a case for developing CPI combinations in non-liver metastatic disease
Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared on LinkedIn:
“I do not often share our publications on LinkedIn. However, this is work that I am particularly proud of. We were the first to define the resistance of liver metastatic disease to IO in MSS CRC and to make a case for developing CPI combinations in non-liver metastatic disease. Here, we go a step further to look at the impact of other sites of metastatic disease on response. LUNG ONLY METASTASES of MSS CRC are CLEALY RESPONSIVE TO IO. We also show that other sites can respond but not to the same level. It is time for the field of oncology (especially MSS Colorectal Cancer) to look at SITES of METASTASES as a Biomarker of response to IO. It is time to start thinking of a composite tissue biomarker and clinical biomarker that includes sites of metastatic disease…”
For the article click here.
Source: Marwan Fakih/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023